

STENOCARE A/S responds to requests from physicians and patients with initiative to expand the medical cannabis product portfolio with capsules

STENOCARE A/S (“STENOCARE”), the leading supplier of medical cannabis for the Danish market, will apply for approval of capsule based medical cannabis products to the Danish Medicines Agency (“DMA”) during the next months. It is STENOCARE’s vision to make a difference for patients, and by adding capsules to its existing oil-based products, STENOCARE will make medical cannabis products more comparable with physician’s prescription of other medical products. At the same time the capsules will offer patients a new dosage form that some will find easier and more comfortable to manage.

STENOCARE is firmly committed to retain its position as first-mover in the Danish market and being able to offer easier dosage form for patients is an important part of STENOCARE’s vision to improve the quality of life for patients. Therefore, and in response to input from physicians, patient organizations and individual patients, STENOCARE is continuously working to identify relevant new products for the Danish market.

As a result, the Board of Directors has decided to formally apply to DMA for approval of three new medical cannabis products, CBD Capsules, THC Capsules and balanced CBD/THC Capsules. The formal applications will be submitted to the Danish Medicines Agency during the next months. The DMA does not offer a commitment for expected approval date, nor a guarantee that the products will be approved or meet the quality requirements for approval. Historically, the Danish Medicines Agency have communicated an expected processing timeline of 6-12 months from submitting an application to a successful approval or rejection.

STENOCARE is currently supplying three oil products to Danish patients, that are sourced from its Canadian partner, CannTrust Inc. With these products, STENOCARE is currently the only supplier of full spectrum oil products under the Danish four-year trial program. Medical cannabis capsules are already offered by STENOCARE’s partner CannTrust for Canadian patients. Subject to approval from DMA, the capsules will be imported from CannTrust. The existing oil-based products are fully compliant with the strict Danish quality and regulatory requirements and this will also apply to the new capsule products.

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO

Phone +45 25326656

E-mail: presse@stenocare.com

This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on November 09, 2018.

STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot programme. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers high quality pharmaceutical grade medical cannabis oil, which is produced by hygienic and high technology cultivation and processing that fully comply with the strict regulatory requirements. STENOCARE will also develop a separate production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.